Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The Global Meningococcal Vaccines Market is poised for impressive growth, projected to expand from USD 4.1 Billion in 2024 to USD 9.3 Billion by 2031. This remarkable growth trajectory, characterized by a Compound Annual Growth Rate (CAGR) of 12%, underscores the critical importance of meningococcal vaccines in combating the spread of N. meningitides infections such as meningitis, meningococcemia, and septicemia.

Market Overview and Key Insights

Meningococcal disease, especially meningococcal meningitis, represents a significant public health challenge, given its highly contagious nature among populations. The disease, which spreads through contact with secretions from the nose and throat of infected individuals, has highlighted the urgent need for effective vaccination programs. The market's expected growth is a testament to the vaccine's role as a cornerstone in preventing these life-threatening conditions.

The meningococcal vaccines market's substantial size, with a 5.5% share in its parent market, reflects its critical role in global health initiatives. The market's expansion is fueled by a combination of public-private partnerships, government efforts to increase vaccination coverage, and the growing incidence of meningitis worldwide.

Demand Analysis and Market Outlook

The period from 2018 to 2023 saw a steady demand for meningococcal vaccines, driven by increased awareness and governmental efforts to combat meningitis outbreaks. The market outlook from 2024 to 2031 is even more promising, with an anticipated surge in demand. This surge is attributed to the increased incidence of meningitis and the rising awareness about the disease among high-risk groups such as preteens, teenagers, and young adults, who account for 21% of meningococcal disease cases.

Key Drivers of Growth

Increased Incidence of Meningitis: With a mortality rate of 5% to 15%, meningococcal disease's severity and the potential for widespread outbreaks have spurred a global increase in vaccine demand.
Increased Awareness: Collaborative efforts by governments, corporations, and non-profit organizations to raise awareness about meningococcal disease and its prevention have significantly contributed to the growth of the vaccination coverage rate globally.
Improved Accessibility: Efforts to improve vaccine accessibility in underdeveloped regions have expanded the market, with companies and global organizations facilitating vaccine procurement and financing.

Market Restraints

Despite the optimistic growth outlook, the meningococcal vaccines market faces challenges, primarily related to limited supply and reliance on a few manufacturers. The market's expansion is further hampered by financial constraints in some countries and a lack of awareness among the general population, which affects vaccination coverage rates.

Competitive Analysis:

The meningococcal vaccines market is highly consolidated, dominated by several major players. These manufacturers are at the forefront of incorporating technical innovations to develop and launch more effective vaccines, thereby enhancing the competitive landscape.

Key Companies Profiled

Sanofi Pasteur Inc.
GlaxoSmithKline
Wyeth Pharmaceuticals

Meningococcal Vaccines Market Segmentation:

Meningococcal Vaccines Market by Product

Polysaccharide Vaccine
Conjugate Vaccine
Serogroup B Vaccine

Meningococcal Vaccines Market by Age Group

Infants (0-24 months)
Children
Adolescents and Young Adults
Adults

Meningococcal Vaccines Market by Distribution Channel

Institutional Sales
Retail Sales

Meningococcal Vaccines Market by Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

1. Executive Summary

1.1. Global Meningococcal Vaccines Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Meningococcal Vaccines Market Outlook, 2018 - 2031

3.1. Global Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Polysaccharide Vaccine
  - 3.1.1.2. Conjugate Vaccine
  - 3.1.1.3. Serogroup B Vaccine
3.2. Global Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Infants (0-24 months)
  - 3.2.1.2. Children
  - 3.2.1.3. Adolescents and Young Adults
  - 3.2.1.4. Adults
3.3. Global Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Institutional Sales
  - 3.3.1.2. Retail Sales
3.4. Global Meningococcal Vaccines Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Meningococcal Vaccines Market Outlook, 2018 - 2031

4.1. North America Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Polysaccharide Vaccine
  - 4.1.1.2. Conjugate Vaccine
  - 4.1.1.3. Serogroup B Vaccine
4.2. North America Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Infants (0-24 months)
  - 4.2.1.2. Children
  - 4.2.1.3. Adolescents and Young Adults
  - 4.2.1.4. Adults
4.3. North America Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Institutional Sales
  - 4.3.1.2. Retail Sales
4.4. North America Meningococcal Vaccines Market Outlook, by Country, Value (US$Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Meningococcal Vaccines Market Outlook, 2018 - 2031

5.1. Europe Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Polysaccharide Vaccine
  - 5.1.1.2. Conjugate Vaccine
  - 5.1.1.3. Serogroup B Vaccine
5.2. Europe Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Infants (0-24 months)
  - 5.2.1.2. Children
  - 5.2.1.3. Adolescents and Young Adults
  - 5.2.1.4. Adults
5.3. Europe Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Institutional Sales
  - 5.3.1.2. Retail Sales
5.4. Europe Meningococcal Vaccines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Meningococcal Vaccines Market Outlook, 2018 - 2031

6.1. Asia Pacific Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Polysaccharide Vaccine
  - 6.1.1.2. Conjugate Vaccine
  - 6.1.1.3. Serogroup B Vaccine
6.2. Asia Pacific Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Infants (0-24 months)
  - 6.2.1.2. Children
  - 6.2.1.3. Adolescents and Young Adults
  - 6.2.1.4. Adults
6.3. Asia Pacific Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Institutional Sales
  - 6.3.1.2. Retail Sales
6.4. Asia Pacific Meningococcal Vaccines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Meningococcal Vaccines Market Outlook, 2018 - 2031

7.1. Latin America Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Polysaccharide Vaccine
  - 7.1.1.2. Conjugate Vaccine
  - 7.1.1.3. Serogroup B Vaccine
7.2. Latin America Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Infants (0-24 months)
  - 7.2.1.2. Children
  - 7.2.1.3. Adolescents and Young Adults
  - 7.2.1.4. Adults
7.3. Latin America Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Institutional Sales
  - 7.3.1.2. Retail Sales
7.4. Latin America Meningococcal Vaccines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Meningococcal Vaccines Market Distribution Channel, Value (US$Bn), 2018 - 2031
  - 7.4.1.4. Mexico Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Meningococcal Vaccines Market Outlook, 2018 - 2031

8.1. Middle East & Africa Meningococcal Vaccines Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Polysaccharide Vaccine
  - 8.1.1.2. Conjugate Vaccine
  - 8.1.1.3. Serogroup B Vaccine
8.2. Middle East & Africa Meningococcal Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Infants (0-24 months)
  - 8.2.1.2. Children
  - 8.2.1.3. Adolescents and Young Adults
  - 8.2.1.4. Adults
8.3. Middle East & Africa Meningococcal Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Institutional Sales
  - 8.3.1.2. Retail Sales
8.4. Middle East & Africa Meningococcal Vaccines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Meningococcal Vaccines Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Meningococcal Vaccines Market by Age Group, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Meningococcal Vaccines Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Distribution Channel Heatmap
9.2. Manufacturer vs Distribution Channel Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. GSK
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Merck
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Pfizer
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Sanofi U.S.
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Novartis
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Wyeth Pharmaceuticals
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Serum Institute of India
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. DJ Lifescience Private Limited
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

List of Region/Countries

North America
- U.S.
- Canada

Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe

Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa